GOG 3026 A phase II trial of letrozole plus ribociclib in women with recurrent low-grade serous carcinoma of the ovary, fallopian tube or peritoneum: A GOG foundation study

The combination of endocrine therapy plus a CDK 4/6 inhibitor has demonstrated superior activity to endocrine therapy alone in multiple clinical trials of women with HR+ breast cancer. We aimed to evaluate the clinical activity of ribociclib (R), an orally bioavailable, highly selective small molecule inhibitor of CDK4/6 plus letrozole (L) in women with recurrent low-grade serous ovarian/peritoneal cancer (LGSOC). We conducted an open-label, single-arm, multi-institution, phase II trial evaluating the efficacy of RL for women with this disease.